Dr Phillip Harrison

 Professional experience

• More than 35 years of experience
• Consultant Hepatologist, London Liver Centre, London Bridge Hospital (1996 - present)
• Consultant Hepatologist, King´s College London (1994 - present)
• General Secretary, British Association for the Study of the Liver (2011 - 2014)
• Accredited endoscopist

...

 Sub-specialties

• Hepatobiliary medicine
• Fatty liver
• Liver disease
• Viral hepatitis
• Liver transplantation
• ERCP
• Portal hypertension
• Primary liver cancer
• Cirrhosis

...

 Teaching posts

• Lectures GPs at London Bridge Hospital
• Senior Lecturer, King´s College London (1994 - 2014)

 Education

• King's College London, Doctor of Philosophy (Ph.D.), Molecular Medicine (1990-1993)
• King's College London Doctor of Medicine (M.D.), Medicine (1989 – 1990)
• St Georges Hospital Medical School Bachelor of Science (BSc), Pharmacology (1978 – 1984)
• St Georges Hospital Medical School Bachelor of Medicine, Bachelor of Surgery (MBBS), Medicine (1978 – 1984)
• Fellow of Royal College of Physicians (London) 1997
• Fellow of Royal College of Physicians (Edinburgh) 2014

...

 Publications and conferences

• Has appeared on national television and contributed to newspapers highlighting liver disease
• Bray GP, Harrison PM, Tredger JM, Gove C, Alexander GJM, Williams R. Later use of N-acetylcysteine in the treatment of acetaminophen overdose. N Eng J Med 1989;320:1417.
• Harrison PM, Keays R, Bray GP, Alexander GJM, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990;335:1572-1573.
• Harrison PM, Wendon JA, Gimson AES, Alexander GJM, Williams R. Improvement by N-acetylcysteine of systemic hemodynamics and oxygen transport in fulminant hepatic failure. N Eng J Med 1991;324:1852-7.
• Basile AS, Hughes RD, Harrison PM, Murata Y, Pannel L, Jones EA, Williams R, Skolnick P. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Eng J Med 1991;325:473-8.
• Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJM, Williams R. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991;303:1026-9.
• Wendon JA, Harrison PM, Keays R, Gimson AES, Alexander GJM, Williams R. Effects of vasopressor agents and epoprostanol on systemic hemodynamics and oxygen transport in fulminant hepatic failure. Hepatology 1992;15:1067-71.
• Gimson AES, Ramage JR, Panos M, Haylar K, Harrison PM, Williams R, Westaby D. Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet 1993; 342:391-4.
• Basile AS, Harrison PM, Hughes RD, Gu Z-Q, Pannel L, McKinney A, Jones EA, Williams R. Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 1994;19:112-21.
• Wendon JA, Harrison PM, Keays R, Williams R. Cerebral blood flow and metabolism in fulminant liver failure. Hepatology 1994;19:1407-13.
• Harrison PM, Degen SJF, Williams R, Farzaneh F. Hepatic expression of Hepatocyte Growth Factor-Like/Macrophage Stimulating protein mRNA in fulminant hepatic failure. Lancet 1994;344:27-9.
• Miwa Y, Harrison PM, Farzaneh F, Langley PG, Williams R, Hughes RD. Plasma levels and hepatic mRNA expression of transforming growth factor-ß1 in patients with fulminant hepatic failure. J Hepatol 1997;27:780-788.
• Harrison PM. Prevention Of Bile Duct Cancer In Primary Sclerosing Cholangitis. Annals of Oncology 1999;10:208-211.
• Wong T, Pereira SP, McNair A, Harrison PM. A prospective, randomized comparison of the ease and safety of variceal ligation using a multiband vs. a conventional ligation device. Endoscopy. 2000;32(12):931-4.
• Heneghan MA, Norris SM, O'Grady JG, Harrison PM, McFarlane IG. Management and outcome of pregnancy in autoimmune hepatitis. Gut. 2001;48(1):97-102.
• Gregorio GV, Portmann B, Karani J, Harrison PM, Donaldson PT, Vergani D, Mieli-Vergani G. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology. 2001;33(3):544-53.
• Norris S, Kondeatis E, Collins R, Satsangi J, Clare M, Chapman R, Stephens H, Harrison PM, Vaughan R, Donaldson P. Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology. 2001;120(6):1475-82.
• Heneghan MA, Byrne A, Harrison PM. An open pilot study of the effects of a human fibrin glue for endoscopic treatment of patients with acute bleeding from gastric varices. Gastrointest Endosc. 2002;56(3):422-6.
• Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison PM, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 2006;94(8):1107-15.
• Xu R, Harrison PM, Chen M, Li L, Tsui TY, Fung PC, Cheung PT, Wang G, Li H, Diao Y, Krissansen GW, Xu S, Farzaneh F. Cytoglobin overexpression protects against damage-induced fibrosis. Mol Ther 2006;13(6):1093-100.
• Orr DW, Harrison PM, Devlin J, Karani JB, Kane PA, Heaton ND, O'Grady JG, Heneghan MA. Chronic Mesenteric Venous Thrombosis: Evaluation and Determinants of Survival During Long-Term Follow-Up. Clin Gastroenterol Hepatol. 2007 Jan;5(1):80-86.
• Tamir A, Basagila E, Kagahzian A, Jiao L, Jensen S, Nicholls J, Tate P, Stamp G, Farzaneh F, Harrison P, Stauss H, George AJ, Habib N, Lechler RI, Lombardi G. Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol Immunother 2007;56(12):2003-16.
• Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, Vergani D, Harrison PM. The increasing prevalence of hepatitis Delta virus (HDV) infection in South London. J Med Virol 2008;80(2):277-82.
• Yeoman AD, Al-Chalabi T, Karani JB, Quaglia A, Devlin J, Mieli-Vergani G, Bomford A, O’Grady JG, Harrison PM, Heneghan MA. Evaluation of Risk Factors in the Development of HCC in AIH: Implications for Follow-up and Screening. Hepatology 2008;48(3):863-70.
• Cross TJS, Rizzi P, Berry PA, Bruce M, Portmann B, Harrison PM. The King’s Score: An Accurate Marker Of Cirrhosis In Chronic Hepatitis C. Eur J Gastroenterol Hepatol 2009;21(7):730-8.
• Cross TJS, Quaglia A, Hughes S, Joshi D, Harrison PM. The Impact of Hepatic Steatosis on the Natural History of Chronic Hepatitis C Infection. J Viral Hepatitis 2009;16:492-9.
• Cross TJS, Quaglia A, Nolan J, Hughes S, Harrison PM. Do steatosis and steatohepatitis impact sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection? J Med Virol 2010;82(6):958-64.
• Cross TJS, Calvaruso V, Maimone S, Carey I, Chang TP, Pleguezuevlo M, Quaglia A, Grillo F, Dhillon AP, Dusheiko GM, Burroughs AK, Harrison PM. Comparison of Transient Elastography, King’s score, and Liver Biopsy for the Assessment of cirrhosis in Chronic Hepatitis C Infection. J Viral Hepatitis 2010;17:546-554.
• Yeoman AD, Westbrook RH, Zen Y, Maninchedda P, Portmann BC, Devlin J, O’Grady JG, Harrison PM, Heneghan MA. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011;53(3):926-34.
• Westbrook RH, Yeoman AD, O'Grady JG, Harrison PM, Devlin J, Heneghan MA. Model for End-Stage Liver Disease Score Predicts Outcome in Cirrhotic Patients During Pregnancy. Clin Gastroenterol Hepatol. 2011;9(8):694-9
• Thokala P, Simpson E, Tappenden P, Stevens J, Dickinson K, Ryder S, Harrison PM. Ledipasvir-Sofosbuvir for treating Chronic Hepatitis C: A NICE Single Technology Appraisal - An Evidence Review Group Perspective. PharmacoEconomics 2016 Aug;34(8):741-50.
• Pinsker N, Papoulas M, Sodergren M, Harrison P, Heaton N, Menon K. Successful endoscopic management of a persistent bronchobiliary fistula with Histoacryl®/Lipiodol® mixture. Ann R Coll Surg Engl. 2018 Apr;100(4):e73-e77.
• O’Beirne J, Harrison PM. The role of the immune system in the control of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2004 16:1-4.
• Cross TJ, Antoniades CG, Harrison PM. Current and future management of chronic Hepatitis C infection. Postgrad Med J 2008 84:172-6.
• Cross TJ, Antoniades CG, Harrison PM. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatology Research 2008 38:762-9.
• Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs 2009;18(11):1655-66.
• Hughes S, Wedemeyer H, Harrison PM. Seminar: Hepatitis D Virus. Lancet. 2011;378(9785):73-85.
• Harrison PM. When Do We Amplify Therapy in Hepatitis B? Viral Hepatitis In Practice 2011; 3(2):4-5.
• Harrison PM. What is changing in Hepatitis B prophylaxis? Viral Hepatitis In Practice 2014; 6(1):7-9.
• Harrison PM. Management of patients with decompensated cirrhosis. Clin Med. 2015;15(2):201-3.
• Nayagam JS, Pereira SP, Devlin J, Harrison PM, Joshi D. Controversies in the management of primary sclerosing cholangitis. World J Hepatol. 2016 Feb 18;8(5):265-72.
• Harrison P, Hogan BJ, Floros L, Davies E; Guideline Development Group. Assessment and management of cirrhosis in people older than 16 years: summary of NICE guidance. BMJ. 2016 Jul 6;354:i2850.

...

 Prizes and awards

• G.R. Giles Prize for innovative research in Hepatology 1994

 Professional membership

• General Secretary of the British Association for the Study of the Liver
• Chair of the NICE Cirrhosis Guideline Development Group